ORIC Pharmaceuticals, Inc. (ORIC)

8,07 +0,40 (+5,22%) Börsenschluss: 04:00PM EDT

ORIC Pharmaceuticals, Inc.

240 East Grand Avenue
2nd Floor
South San Francisco, CA 94080
United States
650 388 5600
https://www.oricpharma.com

Sektor(en): Healthcare
Branche: Biotechnology
Vollzeitmitarbeiter: 100

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Dr. Richard A. Heyman Ph.D.	Co-Founder, Independent Chairman & Member of Scientific Advisory Board	93k	N/A	1957
Dr. Jacob M. Chacko M.B.A., M.D.	President, CEO & Director	961k	N/A	1979
Mr. Dominic G. Piscitelli C.P.A., M.B.A.	Chief Financial Officer	654,74k	N/A	1975
Dr. Pratik S. Multani M.D., M.S.	Chief Medical Officer	715,22k	N/A	1967
Dr. Charles L. Sawyers B.A., M.D., Ph.D.	Co-Founder & Member of Scientific Advisory Board	N/A	N/A	1959
Dr. Scott W. Lowe Ph.D.	Co-Founder & Member of Scientific Advisory Board	N/A	N/A	N/A
Dr. Lori Sickels Friedman Ph.D.	Chief Scientific Officer	N/A	N/A	1964
Dr. Christian V. Kuhlen Esq., J.D., M.D.	General Counsel	N/A	N/A	1973
Mr. Daniel Iazzetti	VP & Head of People	N/A	N/A	N/A
Dr. Edna Chow Maneval	Senior Vice President of Clinical Development	N/A	N/A	1960

Die Beträge haben den Stand 31. Dezember 2023 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in USD.

Beschreibung

ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, which is designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study; and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, currently under Phase 1b study, being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens. The company is also developing multiple discovery stage precision medicines targeting other cancer resistance mechanisms, including ORIC-613, an orally bioavailable, highly selective inhibitor of PLK4, in preclinical studies for the treatment of breast cancers. It has a license and collaboration agreement with Voronoi Inc.; a license agreement with Mirati Therapeutics, Inc.; and clinical development collaboration agreement with Pfizer Inc. The company was incorporated in 2014 and is headquartered in South San Francisco, California.

Corporate Governance

ORIC Pharmaceuticals, Inc.s ISS Governance QualityScore, Stand 1. April 2024, lautet 9. Die grundlegenden Scores sind Audit: 10, Vorstand: 4, Shareholderrechte: 8, Kompensation: 9.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.